Table 52Evidence summary table: perphenazine versus olanzapine

Outcome or SubgroupStudiesParticipantsEffect EstimateI2Favors
Positive Symptoms
PANSS2315971.47 (0.55, 2.40)NEolanzapine
Negative Symptoms
PANSS2315970.43 (−0.55, 1.41)NEND
General Psychopathology
PANSS2315972.17 (0.66, 3.68)NEolanzapine
Global Ratings and Total Scores
CGI–S2315970.25 (0.06, 0.43)NEolanzapine
PANSS231597−4.59 (−7.42, −1.77)NEperphenazine
Employment/Personal Earnings
Paid employment in past month2315971.29 (0.70, 2.38)*NEND
Health Care System Utilization
Rates of hospitalization/rehospitalization2315971.39 (0.92, 2.09)*NEND
Health-Related Quality of Life
QLS Total score2315970.00 (−0.16, 0.16)NEND
Medication Adherence
Time to all-cause medication discontinuation (days)1311277−78.70 (−119.34, −38.06)NEolanzapine

Note: bold = statistically significant;

*

binary outcome;

CGI–S = Clinical Global Impression–Severity; I2 = I-squared; ND = no difference; NE = not estimable; PANSS = Positive and Negative Symptom Scale; QLS = Quality of Life Scale

From: Results

Cover of First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness
First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness [Internet].
Comparative Effectiveness Reviews, No. 63.
Abou-Setta AM, Mousavi SS, Spooner C, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.